Check whether envafolimab plus lenvatinib helps advanced uterine cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the informed consent form and agree to study procedures.
- You have confirmed advanced or metastatic endometrial cancer that can’t be cured with surgery or radiation.
- Your cancer got worse or you couldn’t tolerate first-line platinum chemotherapy (with a rule about relapse within 12 months).
- You have at least one measurable tumor spot on scans (RECIST 1.1), confirmed by an independent imaging review.
- Your general health is good enough (ECOG performance status 0 or 1) and you’re expected to live at least 12 weeks.
- You must have usable tumor tissue available (archived or new biopsy) for biomarker testing before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding a repurposed drug to Keytruda and Lenvima (Len+Pem) helps people with advanced or recurrent endometrial cancer live longer and feel safer. It is designed for tumors that do not have certain immune-system markers (not MSI-H or dMMR).
This Phase 2 trial tests whether a repurposed drug can be safely added to Keytruda and Lenvima for women with advanced or recurrent endometrial cancer. It’s meant to help people who can’t have curative surgery or radiation after prior chemotherapy.
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for endometrial cancer that has come back after initial treatment with chemotherapy and immunotherapy. The study focuses on a specific type of cancer based on genetic testing and may help patients whose cancer didn't respond to standard first-line treatment.
This Phase 2 trial tests whether adding envafolimab (an immunotherapy medicine) to standard chemo and radiation improves outcomes for locally advanced cervical cancer. It may help your immune system better attack the cancer while you receive treatment aimed at cure or long-term control.
Hear when a new Advanced Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.